- AustraliaNorth AmericaWorld
Investing News NetworkYour trusted source for investing success
- Lithium Outlook
- Oil and Gas Outlook
- Gold Outlook Report
- Uranium Outlook
- Rare Earths Outlook
- All Outlook Reports
- Top Generative AI Stocks
- Top EV Stocks
- Biggest AI Companies
- Biggest Blockchain Stocks
- Biggest Cryptocurrency-mining Stocks
- Biggest Cybersecurity Companies
- Biggest Robotics Companies
- Biggest Social Media Companies
- Biggest Technology ETFs
- Artificial Intellgience ETFs
- Robotics ETFs
- Canadian Cryptocurrency ETFs
- Artificial Intelligence Outlook
- EV Outlook
- Cleantech Outlook
- Crypto Outlook
- Tech Outlook
- All Market Outlook Reports
- Cannabis Weekly Round-Up
- Top Alzheimer's Treatment Stocks
- Top Biotech Stocks
- Top Plant-based Food Stocks
- Biggest Cannabis Stocks
- Biggest Pharma Stocks
- Longevity Stocks to Watch
- Psychedelics Stocks to Watch
- Top Cobalt Stocks
- Small Biotech ETFs to Watch
- Top Life Science ETFs
- Biggest Pharmaceutical ETFs
- Life Science Outlook
- Biotech Outlook
- Cannabis Outlook
- Pharma Outlook
- Psychedelics Outlook
- All Market Outlook Reports
Chemistree Technology Inc. (CSE:CHM,OTCQB:CHMJF) was recently featured in a sponsored article published in Cannabis Brightline magazine.
Chemistree Technology Inc. (CSE:CHM,OTCQB:CHMJF) was recently featured in an article published in Cannabis Brightline magazine.
The article touched on the expertise of Chemistree’s management team in the cannabis space. According to the article, Chemistree is backed by cannabis industry experts that have numerous years of experience in building vertically-integrated cannabis companies. The team includes “visionaries” like Chemistree Founder and Strategic Advisor Dennis Hunter, who has made several successful cannabis brands. Joining him is Director and Chief Cannabis Officer Sheldon Aberman, who has extensive experience in designing and building cultivation facilities. Trans High Corporation Director and Chief Cannabis Officer Nicholas Zitelli, who is also the founder and CEO of the Cannabis Genetics Institute, has also recently joined the Chemistree management team. Management is also backed by a “robust capital markets and finance team” that has amassed a track record of success in the public markets.
“Operationally, we have succeeded by virtue of our people. We sort of capitalized on operating successes. We’re not overstretched. We didn’t spend too much money on things we really were not entirely convinced we could manage ourselves very well; we have a disciplined approach to investments,” said Chemistree President Karl Kottmeler.
To learn more about Chemistree and it’s management team, click here.
Latest News
Investing News Network websites or approved third-party tools use cookies. Please refer to the cookie policy for collected data, privacy and GDPR compliance. By continuing to browse the site, you agree to our use of cookies.